IMV - IMV reports mid-stage data on DPX-Survivac in ovarian cancer March, 26 2019 08:35 AM IMV Inc. IMV (NASDAQ:IMV) announces preliminary data from the phase 2 portion of the DECIDE study in patients with advanced recurrent ovarian cancer.More news on: IMV Inc., Healthcare stocks news, Read more ...